Optimizing AAV Safety Summit

Hundreds of clinical trials using AAV are underway, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline, the need to administer high doses, the clinical holds placed on gene therapy trials, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that's fit for purpose!

In this setting, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology, pharmacology, non-clinical study leads, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays.

Join us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics, Ask Bio, Eli Lilly, Takeda, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies, learn how clinical safety signals have changed how companies are approaching their pipeline progression, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.

URLs:
Website: https://go.evvnt.com/1166061-0?pid=176 
Tickets: https://go.evvnt.com/1166061-2?pid=176 
Brochure: https://go.evvnt.com/1166061-3?pid=176 

Time: 9:00 am - 5:15 pm

Prices:
Conference Only - Industry Pricing: USD 2999.00,
Conference + Workshop Day - Industry Pricing: USD 4297.00,
Conference Only - Academic Pricing: USD 2599.00,
Conference + Workshop Day - Academic Pricing: USD 3697.00

Speakers: Anna Majowicz, Preclinical Immunology Lead, Spark Tx, Boris Gorovits, Vice President In Vitro Pharmacology and Bioanalysis, Sana Biotechnology, Charles Venditti, Senior Investigator, NIH, Chris Thompson, Head of Non Clinical Safety, Decibel Therapeutics, David Markusic, Assistant Professor - Research, Indiana University School of Medicine, Denise Sabatino, Associate Professor of Paediatrics, The University of Pennsylvania and The Children's Hospital of Philadelphia, Eric David, Chief Executive Officer, BridgeBio, Genevieve Laforet, Vice President - Clinical Development, Aspa Therapeutics, Gloria Gonzalez, Chief Scientific Officer, Vivet Therapeutics, Hildegund Ertl, Professor, The Wistar Institute, Jean-Philippe, Combal Chief Executive Officer, Vivet Therapeutics, Jeffry Lawrence, Interim Vice President - Clinical Development, Solid Biosciences, Justine Cunningham, Vice President Toxicology and Biodistribution, Sana Biotechnology, Katherine High, President - Therapeutics, AskBio, Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc., Klaudia Kuranda, Head of Immunology, Spark Tx, Madhumita Das, Director - Immunology Discovery, Apellis Pharmaceuticals, Mark Sands, Professor, WUSTL, Michael Franti, Director - DMPK, Boehringer Ingelheim, Nagendra Chemuturi, Director Research, Takeda, Nicholas Buss, Senior Director - Preclinical Development, REGENXBIO, Nicole Paulk, Assistant Professor, AAV Gene Therapy, UCSF, Olga Uspenskaya, Vice President - Clinical Development, Eli Lilly, Richard Samulski, President, Chief Scientific Officer and Cofounder, AskBio, Linda Couto, Chief Scientific Officer, Atsena Tx, Ronald Crystal, Professor and Chairman, Department of Genetic Medicine, Weill Cornell Medical College, Shari Gordon, Senior Director - Immunology, AskBio, Stuart Nelson, Senior Scientist, Eli Lilly, Weidong Xiao, Professor, Indiana University, Zhihua Jiang, Senior Principal Scientist, Pfizer